Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 1,700 shares, a growth of 1,600.0% from the February 28th total of 100 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 27,500 shares, the days-to-cover ratio is presently 0.1 days.
Novozymes A/S Trading Up 1.3 %
Shares of NVZMY stock traded up $0.74 on Friday, reaching $58.47. The company's stock had a trading volume of 22,273 shares, compared to its average volume of 19,406. The company has a market capitalization of $27.38 billion, a price-to-earnings ratio of 37.01, a price-to-earnings-growth ratio of 3.87 and a beta of 0.91. The stock's fifty day simple moving average is $57.94 and its 200-day simple moving average is $60.51. Novozymes A/S has a 1 year low of $52.96 and a 1 year high of $72.50.
Novozymes A/S Increases Dividend
The business also recently disclosed a dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Monday, April 7th will be paid a $0.3758 dividend. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date is Monday, April 7th. Novozymes A/S's dividend payout ratio (DPR) is presently 94.94%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Further Reading
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.